Two cases of acute‐onset cystoid macular edema and serous retinal detachment associated with combined use of encorafenib and binimetinib for advanced melanoma: A possible confounding risk for drug intolerance

Abstract While combined use of BRAF/MEK inhibitors has elicited dramatic clinical efficacy in incurable melanoma, drug‐associated retinopathy become an emerging adverse event. We present two Japanese men with advanced melanoma who developed visual impairment due to serous retinal detachments (SRDs) cystoid macular edema (CME) immediately after initial administration encorafenib/binimetinib, a BRAF and MEK inhibitor. One case had drug‐intolerable on repeat dosing. Both cases were switched another inhibitors, dabrafenib/trametinib, no recurrence SRDs. Co‐existing CME may be confounding risk for the early development SRDs encorafenib/binimetinib therapy, providing attention during drug administration.